Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics.
Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.
seqWell Inc. is a biotechnology company that specializes in gene sequencing and laboratory services, focusing on the development of innovative library preparation technology. Founded in 2014 and based in Beverly, Massachusetts, seqWell offers a range of products and services including paramagnetic beads for nucleic acid purification, library preparation kits, and customized bioinformatics support. Its technology platform facilitates simple and scalable multiplexing of hundreds to thousands of samples, eliminating the need for time-consuming normalization processes. The company markets its products through distributors in various countries, including the United States, Australia, South Korea, and several European nations, as well as through online channels. This approach enables seqWell to enhance the efficiency and consistency of DNA sequencing workflows for its clients.
Pheon Therapeutics is a London-based company established in 2022, specializing in the development of Antibody-Drug Conjugates (ADCs) aimed at addressing a variety of difficult-to-treat cancers. The company focuses on creating next-generation ADCs, with its lead program targeting a novel antigen that is significantly expressed in solid tumors across multiple hard-to-treat cancer types. By enhancing the therapeutic options available to healthcare providers, Pheon Therapeutics aims to provide effective treatment alternatives for patients whose cancers do not respond to existing therapies.
In the simplest sense, we’re a company that creates solutions. More specifically, we design novel access device technology for vascular interventions and unmet clinical needs. Because in the precious seconds that surround a stroke emergency, clinicians need technology that delivers. That’s where we come in.
Translational Drug Development, LLC specializes in preclinical services for oncology medicine development. Founded in 2003 and located in Scottsdale, Arizona, the company provides expertise in regulatory strategy, clinical trial design, and execution tailored specifically for oncology-focused organizations. It offers clients an integrated suite of tools that streamline the research process from preclinical development to regulatory submission. This includes access to over 300 tumor models, bioanalytical support, and advanced equipment for efficacy testing. By facilitating efficient patient recruitment and ensuring alignment with clinical and regulatory standards, Translational Drug Development plays a pivotal role in advancing oncology research and improving the chances of successful drug development.
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics.
Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.
seqWell Inc. is a biotechnology company that specializes in gene sequencing and laboratory services, focusing on the development of innovative library preparation technology. Founded in 2014 and based in Beverly, Massachusetts, seqWell offers a range of products and services including paramagnetic beads for nucleic acid purification, library preparation kits, and customized bioinformatics support. Its technology platform facilitates simple and scalable multiplexing of hundreds to thousands of samples, eliminating the need for time-consuming normalization processes. The company markets its products through distributors in various countries, including the United States, Australia, South Korea, and several European nations, as well as through online channels. This approach enables seqWell to enhance the efficiency and consistency of DNA sequencing workflows for its clients.
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics.
Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.
BioInformatics, LLC is a market research and advisory firm that serves the life science, medical device, pharmaceutical, and diagnostic industries. The company specializes in both primary and secondary research, providing insights on market size, attractiveness, and product optimization. Key services include product concept testing, pricing strategy analysis, customer satisfaction assessments, and brand strength evaluations. BioInformatics helps clients navigate corporate acquisitions and measure brand loyalty, offering tailored research that informs strategic decisions. With a multidisciplinary team of industry veterans and research experts, the firm supports clients in enhancing their market positioning and developing effective marketing strategies. Founded in 1994 and based in Arlington, Virginia, BioInformatics caters to a diverse clientele, including biotechnology firms, medical diagnostics companies, and professional service providers.
Dispersol Technologies LLC specializes in advanced plastics processing technology aimed at improving pharmaceutical manufacturing. The company is known for its proprietary KinetiSol technology, a non-solvent fusion-based process that enhances the solubility and bioavailability of poorly water-soluble drug molecules. This technology facilitates the creation of amorphous solid dispersion systems using a wide range of pharmaceutical polymers. Dispersol offers a comprehensive suite of services, including KinetiSol feasibility studies, formulation development, cGMP manufacturing of amorphous intermediates, and various analytical services such as chemical characterization and stability assessment. The company's solutions cater not only to pharmaceutical manufacturers but also to chemical companies and research institutions. Founded in 2007 and headquartered in Georgetown, Texas, Dispersol Technologies is committed to addressing the challenges associated with oral drug delivery and enhancing the performance of challenging active pharmaceutical ingredients.
OrthAlign, Inc. is a medical device company based in Aliso Viejo, California, specializing in surgical navigation products designed for orthopedic procedures, particularly in joint replacement surgeries. The company offers handheld devices such as KneeAlign for total knee arthroplasty, HipAlign for hip surgeries, and UniAlign for unicompartmental knee arthroplasty. These products utilize precise alignment technology in compact, single-use devices that are compatible with various implant systems. OrthAlign's tools provide critical data related to knee stability, angles, and cup placements, aiming to improve surgical outcomes and enhance patient recovery. The company serves orthopedic surgeons, hospitals, and patients through a global network of distributors, with a mission to establish a new standard of care in total joint replacement. Founded in 2004, OrthAlign was previously known as Vitruvian Orthopaedics, Inc. and rebranded in 2009.
Rubicon Genomics, Inc. is a biotechnology company based in Ann Arbor, Michigan, specializing in nucleic acid library preparation and amplification technologies for clinical research applications. Founded in 2000 by University of Michigan faculty members, the company focuses on developing innovative products that enhance the sensitivity of DNA analysis. Its product lineup includes the ThruPLEX and PicoPLEX kits, which utilize ligation-based and quasi-random primed amplification methods, respectively. These products enable the analysis of small amounts of DNA from various sources, including plasma and tissue samples. Rubicon's technologies are particularly notable for their ability to detect DNA methylation patterns associated with cancer, facilitating non-invasive diagnostic tests that can aid physicians in identifying diseases. The company markets its products both directly and through distributors, emphasizing its commitment to advancing human genetics into practical medical applications while supporting the local economy. Rubicon Genomics operates as a subsidiary of Takara Bio USA Holdings, Inc.
CyMedica develops and commercializes innovative products that target joint injuries and the resulting muscle atrophy. Its mission is to address this problem with proprietary neuromuscular electrical stimulation. The company's platform technology utilizes the first closed-loop power control systems to provide patients with comfortable yet aggressive treatment.
It was founded in 2013 and headquartered in Scottsdale, Arizona.
Dispersol Technologies LLC specializes in advanced plastics processing technology aimed at improving pharmaceutical manufacturing. The company is known for its proprietary KinetiSol technology, a non-solvent fusion-based process that enhances the solubility and bioavailability of poorly water-soluble drug molecules. This technology facilitates the creation of amorphous solid dispersion systems using a wide range of pharmaceutical polymers. Dispersol offers a comprehensive suite of services, including KinetiSol feasibility studies, formulation development, cGMP manufacturing of amorphous intermediates, and various analytical services such as chemical characterization and stability assessment. The company's solutions cater not only to pharmaceutical manufacturers but also to chemical companies and research institutions. Founded in 2007 and headquartered in Georgetown, Texas, Dispersol Technologies is committed to addressing the challenges associated with oral drug delivery and enhancing the performance of challenging active pharmaceutical ingredients.
Providence Medical Technology is a privately-held medical device company focused on innovative solutions for cervical spinal conditions. The company has pioneered a proprietary approach to cervical fusion and has developed surgical instrumentation and implants that offer unique benefits to the $2 billion worldwide cervical spine market. The Providence family of products includes the DTRAX® Spinal Instrumentation System, CAVUX® intervertebral implants, and the ALLY® line of bone and facet screws. All products are shipped-sterile and single-use to maximize perioperative efficiency and ensure consistent quality and performance.
ClearFlow, Inc., a medical device company, develops and manufactures active blood and fluid evacuation systems to medical tube obstructions. It offers PleuraFlow Active Clearance Technology, a system that clears chest tubes and prevents the retention of blood and fluids in the chest cavity, as well as treats pediatric cardiothoracic surgery patients. The company’s product pipeline is based on its proprietary Active Clearance Technology to resolve catheter clogging in multiple medical market segments, including urinary catheters, gastrointestinal catheters, and wound drainage. ClearFlow, Inc. was formerly known as Clear Catheter Systems, Inc. and changed its name to ClearFlow, Inc. in March 2014. The company was incorporated in 2006 and is based in Anaheim, California. It has a service center in Maastricht, the Netherlands.
OrthAlign, Inc. is a medical device company based in Aliso Viejo, California, specializing in surgical navigation products designed for orthopedic procedures, particularly in joint replacement surgeries. The company offers handheld devices such as KneeAlign for total knee arthroplasty, HipAlign for hip surgeries, and UniAlign for unicompartmental knee arthroplasty. These products utilize precise alignment technology in compact, single-use devices that are compatible with various implant systems. OrthAlign's tools provide critical data related to knee stability, angles, and cup placements, aiming to improve surgical outcomes and enhance patient recovery. The company serves orthopedic surgeons, hospitals, and patients through a global network of distributors, with a mission to establish a new standard of care in total joint replacement. Founded in 2004, OrthAlign was previously known as Vitruvian Orthopaedics, Inc. and rebranded in 2009.
OrthAlign, Inc. is a medical device company based in Aliso Viejo, California, specializing in surgical navigation products designed for orthopedic procedures, particularly in joint replacement surgeries. The company offers handheld devices such as KneeAlign for total knee arthroplasty, HipAlign for hip surgeries, and UniAlign for unicompartmental knee arthroplasty. These products utilize precise alignment technology in compact, single-use devices that are compatible with various implant systems. OrthAlign's tools provide critical data related to knee stability, angles, and cup placements, aiming to improve surgical outcomes and enhance patient recovery. The company serves orthopedic surgeons, hospitals, and patients through a global network of distributors, with a mission to establish a new standard of care in total joint replacement. Founded in 2004, OrthAlign was previously known as Vitruvian Orthopaedics, Inc. and rebranded in 2009.
Esperance Pharmaceuticals Inc. develops targeted anticancer drugs to treat women with ovarian and breast cancer. Its products include EP-100, an oncolytic peptide that seeks and destroys cancer cells that express receptors for luteinizing hormone releasing hormone (LHRH), and selectively kill cancer cells without harming normal cells. The company has strategic alliance with MD Anderson Cancer Center to accelerate clinical development of EP-100 for the treatment of women with ovarian cancer and breast cancer. Esperance Pharmaceuticals Inc. was incorporated in 2005 and is based in Houston, Texas.
Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.
Esperance Pharmaceuticals Inc. develops targeted anticancer drugs to treat women with ovarian and breast cancer. Its products include EP-100, an oncolytic peptide that seeks and destroys cancer cells that express receptors for luteinizing hormone releasing hormone (LHRH), and selectively kill cancer cells without harming normal cells. The company has strategic alliance with MD Anderson Cancer Center to accelerate clinical development of EP-100 for the treatment of women with ovarian cancer and breast cancer. Esperance Pharmaceuticals Inc. was incorporated in 2005 and is based in Houston, Texas.
Cantex Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative cancer treatments. The company specializes in repurposing established therapies to create safer and more effective options for patients. Its lead product, ODSH, is a modified low anticoagulant heparin derivative designed to mitigate the adverse effects of chemotherapy on platelet counts. Additionally, Cantex offers Disulfiram-Copper Chelate, which targets multiple mechanisms to eliminate cancer stem cells, particularly for metastatic breast cancer, pancreatic cancer, and glioblastoma. By addressing significant unmet medical needs, Cantex Pharmaceuticals aims to provide high-value therapeutic solutions in the oncology market. Founded in 2002 and based in Weston, Florida, the company was previously known as PARINGENIX INC.
Cantex Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative cancer treatments. The company specializes in repurposing established therapies to create safer and more effective options for patients. Its lead product, ODSH, is a modified low anticoagulant heparin derivative designed to mitigate the adverse effects of chemotherapy on platelet counts. Additionally, Cantex offers Disulfiram-Copper Chelate, which targets multiple mechanisms to eliminate cancer stem cells, particularly for metastatic breast cancer, pancreatic cancer, and glioblastoma. By addressing significant unmet medical needs, Cantex Pharmaceuticals aims to provide high-value therapeutic solutions in the oncology market. Founded in 2002 and based in Weston, Florida, the company was previously known as PARINGENIX INC.
NP Photonics, Inc. designs and produces optical light sources for sensing, medical, and research and development markets. It offers fiber and single-frequency lasers, amplified spontaneous emission sources, fiber amplifiers, and light sources. It offers its products through distributors in Australia, Belgium, France, Germany, Israel, Japan, South Korea, Spain, Sweden, Denmark, Iceland, Norway, Finland, the Netherlands, the People's Republic of China, and the United Kingdom. NP Photonics, Inc. was formerly known as NP Photonic Technologies, LLC and it changed its name in August 2000. The company was founded in 1998 and is based in Tucson, Arizona.